(Toronto, Ontario; February 5, 2026) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, today announced the extension of its Research and Exclusive Option Agreement (the “Agreement”) with metaShape Pharma AG (“metaShape”) covering LEUMUNA™ through December 31, 2028. The Agreement was originally entered into in April 2023 between metaShap ...